Advancements in Microbial Drug Discovery: Leveraging AI, CRISPR, and Microbiome Insights to Overcome Antimicrobial Resistance

Ibrahim Abdulrazaq; Shehu-Alimi Elelu; Ganiyat Omotayo Ibrahim; Idowu Afeez Temitope; Abdulsalam Hawau Avoswahi; Abdulkareem Tajuddeen Zakari; Mustapha Abdulsalam

doi:10.55006/biolsciences.2025.5304

Authors

Ibrahim Abdulrazaq Department of Microbiology, University of Ilorin, Nigeria https://orcid.org/0009-0001-6107-0331
Shehu-Alimi Elelu Department of Chemistry, Howard University, Washington DC, USA
Ganiyat Omotayo Ibrahim Department of Chemistry, Nottingham Trent University, UK
Idowu Afeez Temitope Department of Medicinal Research, Kaohsiung Medical University Hospital, Taiwan https://orcid.org/0009-0006-5685-9078
Abdulsalam Hawau Avoswahi Department of Computer Sciences, University of Ilorin, Nigeria
Abdulkareem Tajuddeen Zakari Department of Microbiology, University of Ilorin, Nigeria https://orcid.org/0009-0006-5950-7668
Mustapha Abdulsalam Department of Microbiology, Skyline University, Nigeria https://orcid.org/0000-0001-7969-0822

DOI:

https://doi.org/10.55006/biolsciences.2025.5304

Keywords:

Artificial intelligence, CRISPR technology, Antimicrobial resistance, Microbiome, Drug discovery

Abstract

This study explores the innovative intersection of artificial intelligence (AI), CRISPR technology, and microbiome insights in microbial drug discovery, with a focus on overcoming the challenges posed by antimicrobial resistance (AMR) and emerging infectious diseases. The global threat of AMR necessitates the development of novel approaches that transcend traditional drug discovery methods. AI-driven platforms, including machine learning and high-throughput screening, are transforming drug design by enabling rapid identification of potential therapeutic targets and optimizing drug repurposing efforts. CRISPR-based gene-editing technologies offer precise tools to combat resistance mechanisms at the genetic level, while microbiome-based therapies hold promise for restoring microbial balance and improving immune responses. Despite significant progress, several challenges remain, including the integration of these technologies, data quality concerns, and the clinical translation of innovative solutions. The future of microbial drug discovery lies in the synergy of these technologies, providing a pathway toward personalized, effective treatments and combating the growing threat of AMR. This study provides a comprehensive overview of the current landscape, identifies research gaps, and outlines potential directions for future advancements.

Downloads

Download data is not yet available.

References

1. Nanayakkara AK, Boucher HW, Fowler Jr VG, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. CA Cancer J Clin. 2021;71(6):488-504.

2. Menz BD, Charani E, Gordon DL, Leather AJ, Moonesinghe SR, Phillips CJ. Surgical antibiotic prophylaxis in an era of antibiotic resistance: common resistant bacteria and wider considerations for practice. Infect Drug Resist. 2021;14:5235-52.

3. Yamanaka H, Tanaka E, Nakajima A, Furuya T, Ikari K, Taniguchi A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today’s treatment options. Mod Rheumatol. 2020;30(1):1-6.

4. Brown DG, Wobst HJ. A decade of FDA-approved drugs (2010–2019): trends and future directions. J Med Chem. 2021;64(5):2312-38.

5. Willis LD, Chandler C. Quick fix for care, productivity, hygiene, and inequality: reframing the entrenched problem of antibiotic overuse. BMJ Glob Health. 2019;4(4):e001590.

6. Cardoso MH, Orozco RQ, Rezende SB, Rodrigues G, Oshiro KG, Cândido ES, et al. Computer-aided design of antimicrobial peptides: are we generating effective drug candidates? Front Microbiol. 2020;10:3097.

7. Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets, and drug-target interactions. Drug Resist Updat. 2020;48:100662.

8. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Nina PB, et al. Futuristic non-antibiotic therapies to combat antibiotic resistance: A review. Front Microbiol. 2021;12:609459.

9. Boolchandani M, D’Souza AW, Dantas G. Sequencing-based methods and resources to study antimicrobial resistance. Nat Rev Genet. 2019;20(6):356-70.

10. Abdulsalam M, Salihu AT, Usman HY, Usman MY. Protein Biosynthesis in Microorganisms: Mechanisms, Regulation, and Biotechnological Applications. World J Adv Res Rev. 2024;21(1):869-81.

11. Farha MA, Brown ED. Drug repurposing for antimicrobial discovery. Nat Microbiol. 2019;4(4):565-77.

12. Abdulsalam M, Musa IO, Livinus MU, Elelu SA, Ibrahim GO, Salami OL, et al. Blue Bioeconomy and Biomedical Innovation. In: Marine Bioprospecting for Sustainable Blue-bioeconomy. Cham: Springer Nature Switzerland; 2024. p. 143-57.

13. Ezzat A, Wu M, Li XL, Kwoh CK. Computational prediction of drug-target interactions using chemogenomic approaches: an empirical survey. Brief Bioinform. 2019;20(4):1337-57.

14. Saheed YK, Salau-Ibrahim TT, Abdulsalam M, Adeniji IA, Balogun BF. Modified bi-directional long short-term memory and hyperparameter tuning of supervised machine learning models for cardiovascular heart disease prediction in the mobile cloud environment. Biomed Signal Process Control. 2024;94:106319.

15. Abushaheen MA, Fatani AJ, Alosaimi M, Mansy W, George M, Acharya S, et al. Antimicrobial resistance, mechanisms, and its clinical significance. Dis Mon. 2020;66(6):100971.

16. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with the host, technology advances, and emerging therapeutics. Signal Transduct Target Ther. 2022;7(1):199.

17. Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, et al. Progress in alternative strategies to combat antimicrobial resistance: Focus on antibiotics. Antibiotics (Basel). 2022;11(2):200.

18. Balsalobre L, Blanco A, Alarcón T. Beta‐lactams. In: Antibiotic drug resistance. Hoboken: John Wiley & Sons, Inc.; 2019. p. 57-72.

19. Bu F, Liu M, Xie Z, Chen X, Li G, Wang X. Targeted anti-biofilm therapy: Dissecting targets in the biofilm life cycle. Pharmaceuticals (Basel). 2022;15(10):1253.

20. Emmerich CH, Gamboa LM, Hofmann MC, Bonin-Andresen M, Arbach O, Schendel P, et al. Improving target assessment in biomedical research: the GOT-IT recommendations. Nat Rev Drug Discov. 2021;20(1):64-81.

21. Abdulsalam M, Fatima ZYU, Hasiya UA, Ummulkhuthum AT, Aisha WN, Muhammad FY. Deciphering the Genetic Code: Mechanisms, Evolution, and Implications for Biotechnology. World J Adv Res Rev. 2024;21(1):858-68.

22. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492-506.

23. Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329-38.

24. Maruyama M, Rhee C, Utsunomiya T, Zhang N, Ueno M, Yao Z, et al. Modulation of the inflammatory response and bone healing. Front Endocrinol (Lausanne). 2020;11:386.

25. Zhang A, Meng K, Liu Y, Pan Y, Qu W, Chen D, et al. Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences. Adv Colloid Interface Sci. 2020;284:102261.

26. Hu X, Zhang H, Wang Y, Shiu BC, Lin JH, Zhang S, et al. Synergistic antibacterial strategy based on photodynamic therapy: Progress and perspectives. Chem Eng J. 2022;450:138129.

27. Shah T, Baloch Z, Shah Z, Cui X, Xia X. The intestinal microbiota: impacts of antibiotics therapy, colonization resistance, and diseases. Int J Mol Sci. 2021;22(12):6597.

28. Conti P, Ronconi G, Caraffa AL, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327-31.

29. Bar Yehuda S, Axlerod R, Toker O, Zigman N, Goren I, Mourad V, et al. The association of inflammatory bowel diseases with autoimmune disorders: a report from the epi-IIRN. J Crohns Colitis. 2019;13(3):324-9.

30. Raheem A, Liang L, Zhang G, Cui S. Modulatory effects of probiotics during pathogenic infections with emphasis on immune regulation. Front Immunol. 2021;12:616713.

31. Stensland KD, DePorto K, Ryan J, Kaffenberger S, Reinstatler LS, Galsky M, et al. Estimating the rate and reasons of clinical trial failure in urologic oncology. Urol Oncol. 2021;39(3):154-60.

32. Basu S, Naha A, Veeraraghavan B, Ramaiah S, Anbarasu A. In silico structure evaluation of BAG3 and elucidating its association with bacterial infections through protein-protein and host‐pathogen interaction analysis. J Cell Biochem. 2022;123(1):115-27.

33. Saheed YK, Balogun BF, Odunayo BJ, Abdulsalam M. Microarray gene expression data classification via Wilcoxon sign rank sum and novel Grey Wolf optimized ensemble learning models. IEEE/ACM Trans Comput Biol Bioinform. 2023;20(6):3575-87.

34. Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from the bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500-25.

35. Gulliver EL, Young RB, Chonwerawong M, D'Adamo GL, Thomason T, Widdop JT, et al. The future of microbiome‐based therapeutics. Aliment Pharmacol Ther. 2022;56(2):192-208.

36. Abdulsalam M, Natour S, Rabiu IB, Abdulazeez M. Microbial Magic: Decoding the Impact of Hypoxia on Exercise Physiology through Microbiota Dynamics. Biol Sci. 2024;4(3):736-45.

37. Dias R, Torkamani A. Artificial intelligence in clinical and genomic diagnostics. Genome Med. 2019;11(1):70.

38. Thapa C, Camtepe S. Precision health data: Requirements, challenges and existing techniques for data security and privacy. Comput Biol Med. 2021;129:104130.

39. Abdulsalam M. Exploring the Therapeutic Promise of Cationic Antibacterial Peptides. Biol Sci. 2024;4(3):692-700.

40. Musa IO, Isibor PO, Samuel JO, Mustapha A, Akande S, Adeniji H. Introduction to Nanotoxicology. In: Environmental Nanotoxicology: Combatting the Minute Contaminants. Cham: Springer Nature Switzerland; 2024. p. 1-22.

41. Lin H, He QY, Shi L, Sleeman M, Baker MS, Nice EC. Proteomics and the microbiome: pitfalls and potential. Expert Rev Proteomics. 2019;16(6):501-11.

42. Abdulsalam M, Amina AA, Ummulkhair AY, Zainab HF. Advances in understanding the interplay between Mutagenesis and DNA repair: Implications for Genomic Stability and Evolution. Int J Sci Acad Res. 2023;4(10):6428-38.

43. Abdulsalam M, Hamisu AA, Ahmad AM, Wakili FB, Annu FS, Garba MM. Microbiome Dynamics and Strategic Management Strategies: Exploring Synergies between Integrative Medicine Modalities and Microbial Balance. Biol Sci. 2024;4(3):725-35.

44. Su M, Zhang Z, Zhou L, Han C, Huang C, Nice EC. Proteomics, personalized medicine, and cancer. Cancers (Basel). 2021;13(11):2512.

45. Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis. 2020;21(3):147-59.

46. Wu Y, Battalapalli D, Hakeem MJ, Selamneni V, Zhang P, Draz MS, et al. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections. J Nanobiotechnology. 2021;19(1):401.

47. Shan S. The controls of nutrient limitation on resource allocation belowground (dissertation). Oxford (OH): Miami University; 2019.

48. Yella A, Kondam A. Big Data Integration and Interoperability: Overcoming Barriers to Comprehensive Insights. Adv Comput Sci. 2022;5(1).

49. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.

50. Lopatkin AJ, Collins JJ. Predictive biology: modeling, understanding and harnessing microbial complexity. Nat Rev Microbiol. 2020;18(9):507-20.

51. Abdulsalam M, Hamisu AA, Ahmad AM, Wakili FB, Rabiu IB, Burodo RA, et al. Synergies at the Intersection: Exploring the Role of Bioinformatics in Enhancing Physiotherapy and Nursing Practice. Biol Sci. 2024;4(3):712-24.

52. Failli M, Paananen J, Fortino V. Prioritizing target-disease associations with novel safety and efficacy scoring methods. Sci Rep. 2019;9(1):9852.

53. Kalelkar PP, Riddick M, García AJ. Biomaterial-based antimicrobial therapies for the treatment of bacterial infections. Nat Rev Mater. 2022;7(1):39-54.

54. Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125-51.

55. Melo MC, Maasch JR, de la Fuente-Nunez C. Accelerating antibiotic discovery through artificial intelligence. Commun Biol. 2021;4(1):1050.

56. Van Esse HP, Reuber TL, van der Does D. Genetic modification to improve disease resistance in crops. New Phytol. 2020;225(1):70-86.

57. Abdulsalam M, Tiamiyu BB, Abdulrazaq I, Salam OL. Comparative Antimicrobial Properties of a Consortium of Nauclea latifolia Sm. and Ocimum gratissium L. Extracts with Their CuO Nanoparticle Multiplexes. Biol Sci. 2023;3(1):386-93.

58. Branda F, Scarpa F. Implications of Artificial Intelligence in Addressing Antimicrobial Resistance: Innovations, Global Challenges, and Healthcare’s Future. Antibiotics (Basel). 2024;13(6):502.

59. Mistry J, Ganesh A. An Analysis of IoT-Based Solutions for Congenital Heart Disease Monitoring and Prevention. J Xidian Univ. 2023;17(7):325-34.

60. van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, et al. Developmental roadmap for antimicrobial susceptibility testing systems. Nat Rev Microbiol. 2019;17(1):51-62.